TRxADE HEALTH Past Earnings Performance
Past criteria checks 0/6
TRxADE HEALTH's earnings have been declining at an average annual rate of -47.7%, while the Healthcare Services industry saw earnings growing at 2.8% annually. Revenues have been growing at an average rate of 6.3% per year.
Key information
-47.7%
Earnings growth rate
-41.6%
EPS growth rate
| Healthcare Services Industry Growth | 1.7% |
| Revenue growth rate | 6.3% |
| Return on equity | -2,529.8% |
| Net Margin | -165.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
TRxADE Health prices of $1.8M stock offering
Oct 05TRxADE Health launches next day delivery services via Trxade prime plus program
Aug 30TRxADE Health proposes public stock offering
Aug 23Trxade Group GAAP EPS of -$0.13 misses by $0.05, revenue of $3.3M beats by $0.37M
Jul 25Will TRxADE HEALTH (NASDAQ:MEDS) Spend Its Cash Wisely?
Mar 30
Here's Why We're Watching TRxADE HEALTH's (NASDAQ:MEDS) Cash Burn Situation
Nov 23Need To Know: Analysts Just Made A Substantial Cut To Their TRxADE HEALTH, Inc. (NASDAQ:MEDS) Estimates
Jul 29Pharma Pain Points - Trxade CEO Suren Ajjarapu (Video)
Jun 16SpartanNash and Bonum Health join hands to provide telemedicine services
Jun 07Shareholders Will Probably Hold Off On Increasing Trxade Group, Inc.'s (NASDAQ:MEDS) CEO Compensation For The Time Being
May 22Earnings Release: Here's Why Analysts Cut Their Trxade Group, Inc. (NASDAQ:MEDS) Price Target To US$10.00
Apr 28Time To Worry? Analysts Just Downgraded Their Trxade Group, Inc. (NASDAQ:MEDS) Outlook
Apr 01Did Business Growth Power Trxade Group's (NASDAQ:MEDS) Share Price Gain of 143%?
Feb 05Revenue & Expenses BreakdownBeta
How TRxADE HEALTH makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8 | -14 | 10 | 0 |
| 30 Sep 23 | 9 | -4 | 8 | 0 |
| 30 Jun 23 | 9 | -4 | 8 | 0 |
| 31 Mar 23 | 10 | -3 | 8 | 0 |
| 31 Dec 22 | 10 | -2 | 8 | 0 |
| 30 Sep 22 | 10 | -3 | 8 | 0 |
| 30 Jun 22 | 11 | -4 | 9 | 0 |
| 31 Mar 22 | 10 | -6 | 9 | 0 |
| 31 Dec 21 | 10 | -5 | 8 | 0 |
| 30 Sep 21 | 9 | -7 | 8 | 1 |
| 30 Jun 21 | 13 | -5 | 7 | 1 |
| 31 Mar 21 | 18 | -3 | 7 | 1 |
| 31 Dec 20 | 17 | -3 | 7 | 1 |
| 30 Sep 20 | 17 | -1 | 6 | 1 |
| 30 Jun 20 | 13 | -1 | 6 | 1 |
| 31 Mar 20 | 8 | 0 | 4 | 1 |
| 31 Dec 19 | 7 | 0 | 4 | 1 |
| 30 Sep 19 | 7 | 0 | 3 | 1 |
| 30 Jun 19 | 6 | 0 | 3 | 1 |
| 31 Mar 19 | 4 | 0 | 3 | 1 |
| 31 Dec 18 | 4 | 0 | 3 | 1 |
| 30 Sep 18 | 3 | 0 | 3 | 0 |
| 30 Jun 18 | 3 | 0 | 3 | 0 |
| 31 Mar 18 | 3 | 0 | 3 | 0 |
| 31 Dec 17 | 3 | 0 | 3 | 0 |
| 30 Sep 17 | 3 | 0 | 3 | 0 |
| 30 Jun 17 | 3 | 0 | 3 | 0 |
| 31 Mar 17 | 3 | -1 | 3 | 0 |
| 31 Dec 16 | 2 | -1 | 3 | 0 |
| 30 Sep 16 | 1 | -1 | 3 | 0 |
| 30 Jun 16 | 2 | -1 | 3 | 0 |
| 31 Mar 16 | 3 | 0 | 3 | 0 |
| 31 Dec 15 | 3 | 0 | 3 | 0 |
| 30 Sep 15 | 4 | -1 | 4 | 0 |
| 30 Jun 15 | 3 | -1 | 3 | 0 |
| 31 Mar 15 | 2 | -2 | 3 | 0 |
| 31 Dec 14 | 1 | -2 | 2 | 0 |
| 30 Sep 14 | 1 | -3 | 3 | 0 |
| 30 Jun 14 | 1 | -3 | 3 | 0 |
| 31 Mar 14 | 1 | -3 | 2 | 0 |
| 31 Dec 13 | 1 | -2 | 2 | 0 |
Quality Earnings: MEDS is currently unprofitable.
Growing Profit Margin: MEDS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MEDS is unprofitable, and losses have increased over the past 5 years at a rate of 47.7% per year.
Accelerating Growth: Unable to compare MEDS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MEDS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (15.4%).
Return on Equity
High ROE: MEDS has a negative Return on Equity (-2529.82%), as it is currently unprofitable.